This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Source: OpenUrlAbstract/FREE Full Text
Investigators from the University of Florida, Gainesville, conducted a retrospective cohort study to evaluate the effect of use of albuterol containing the preservative benzalkonium chloride (BAC) for continuous nebulization on patient outcomes. Single-dose albuterol products are preservative-free, while multidose preparations contain BAC. The multidose preparations allow for easier and faster pharmacy preparation for continuous nebulization, but BAC has been shown to cause bronchospasm.1 At the University of Florida Health Shands Children’s Hospital, preservative-free albuterol was used for continuous nebulization until October 2015, when the switch was made to the preparation with BAC. For the current study, the authors identified patients treated during the 18-month period before the change (control group) and those treated in the 18-month period after the change (BAC group) for inclusion in the study. Data on demographics, oxygen saturation, and a standardized asthma …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.